SummaryAhead of the American Society of Clinical Oncology's annual meeting, Avalere experts discussed the latest trends in policy, reimbursement, and market access reshaping oncology care.
The oncology landscape continues to see significant changes as public focus on costs is amplified by drug pricing reforms, providers take on more financial risk, and clinical advancements outpace existing regulatory and reimbursement mechanisms. Provider participation in initiatives such as the Oncology Care Model (OCM) has spurred transformation in oncology care necessitating life science companies to seek new ways to demonstrate value. It is critical to understand how implementation of new reforms and initiatives could impact providers and patients from an access, quality, and affordability perspective.
On May 21, Avalere experts unpacked the complex dynamics stakeholders must consider, spanning policy, market access and reimbursement, and regulatory implications. Meet with us at the annual meeting of the American Society of Clinical Oncology to continue the conversation.
- Impact of drug pricing policy proposals
- Evolution of the OCM
- Reimbursement approaches to novel therapies (e.g., CAR-T)
- Evidence Generation and FDAMA 114 Opportunities
- Differential pricing for combination and multi-indication regimens
produces measurable results. Let's work together.